Visium Asset Management’s Puma Biotechnology PBYI Stock Holding History

Visium Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-215,924	Closed	-$6.34M	–	449
2016 Q1	$6.34M	Buy	+215,924	New	+$9.76M	0.11%	221
2015 Q3	–	Sell	-19,247	Closed	-$2.25M	–	1120
2015 Q2	$2.25M	Buy	19,247 +17,994	+1,436%	+$3.26M	0.03%	405
2015 Q1	$296K	Buy	+1,253	New	+$268K	﹤0.01%	814

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Visium Asset Management's PBYI Position: Q2 2016 in Review

Visium Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2016, closing a stake of 215,924 shares — an estimated $6.34M sold.

Visium Asset Management first reported a position in PBYI in Q1 2015 and held it in 3 quarters. The position peaked at $6.34M in Q1 2016. 110 funds tracked by Wall St. Rank hold PBYI as of Q2 2016.

Visium Asset Management reported no remaining Puma Biotechnology position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 215,924 Puma Biotechnology shares in Q2 2016, an estimated $6.34M.
Visium Asset Management first reported a position in Puma Biotechnology in Q1 2015 and held it in 3 quarters.
Visium Asset Management's Puma Biotechnology position peaked at $6.34M in Q1 2016.
110 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.